Abstract:ID 87764 Poster Board 443 Small molecule activators of the mitochondrial matrix protease, caseinolytic protease proteolytic subunit (ClpP), are under investigation for the treatment of aggressive and resilient cancers. Exemplified by the imipridones (ONC201/206, Chimerix), these and related analogs (TR compounds, Madera Therapeutics), disrupt multiple mitochondrial processes required for cancer cell growth. These ClpP agonists induce ClpP-dependent degradation of select matrix proteins, interrupting TCA cycle function, OXPHOS and mitochondrial metabolism, culminating in cancer cell senescence. Our investigation demonstrated that ClpP agonists also cause the degradation of select protein components of the mitochondrial import machinery known as the presequence translocase-associated motor (PAM) complex. Further experimentation demonstrated a concomitant cytosolic accumulation of the senescence-associated mitochondrial matrix protein GRSF1, indicating impairment of import. The goal of this study was to investigate how ClpP activation affects PAM complex proteins and how disruption of this translocase process impacts mitochondrial protein import and function. ClpP-dependent changes in mitochondrial protein abundance were investigated by immunoblotting. Subcellular localization of proteins was determined by manual fractionation of samples into mitochondrial and cytosolic fractions. Log fold changes in PAM complex protein levels were also determined via a global proteomics screen and quantitative peptide analysis using mass spectrometry. All experiments were done in wildtype, triple-negative breast cancer cells (TNBC cells: SUM159, MDA-MB-231) or their corresponding ClpP-knockout derivatives. Following ClpP-agonist treatment of TNBC cells, we detected a ~15 kDa increase in the molecular weight (MW) of the senescence-associated protein GRSF1 by immunoblot. This increase in MW was consistent with retention of the mitochondrial transit sequence (MTS), which is normally cleaved following import into the mitochondrial matrix. Subcellular fractionation revealed accumulation of the higher-weight GRSF1 (65 kDa) in the cytosolic fraction and a depletion of the lower-weight GRSF1 (50 kDa) from the mitochondrial fraction. Parallel proteomics data revealed a ClpP-agonist-dependent decrease in several PAM complex proteins (GRPEL1/2, TIMM44). The decline in GRPEL1 was validated by immunoblot analysis. Finally, the knockdown of specific PAM complex proteins was examined to confirm the effects of PAM complex protein loss on GRSF1 mitochondrial import. Our proteomics data that demonstrated a ClpP-dependent decrease in PAM complex proteins, suggested that mitochondrial protein import would be impaired. Following the fate of GRSF1, we confirmed this hypothesis and highlighted the importance of specific PAM complex proteins in this process. Similar MW shifts were observed with other mitochondrial matrix proteins (ALAS1, GPT2), suggesting broad effects of ClpP agonists on mitochondrial protein import. Previous studies showed that knockdown and inhibition of GRSF1's mitochondrial function was linked to increased senescence. Our data demonstrating ClpP-dependent inhibition of mitochondrial import suggests that this may be another mechanism by which ClpP agonists disrupt GRSF1 function and facilitate the development of senescence in TNBC. NIH GM ROI 138520 Drug-induced ClpP activation leads to PAM complex and mitochondrial matrix GRSF1 degradation

LONP1 and ClpP cooperatively regulate mitochondrial proteostasis for cancer cell survival

Mitochondrial Lon Protease and Cancer.

The Mitochondrial Unfoldase-Peptidase Complex ClpXP Controls Bioenergetics Stress and Metastasis

Abstract 446: LONP1 inhibition induces mitochondrial proteotoxic stress and is cytotoxic to acute myeloid leukemia cells

Mitochondrial quality control proteases and their modulation for cancer therapy

Abstract 5898: Inhibition of the LONP1 ATPase domain induces mitochondrial proteotoxic stress and is cytotoxic to acute myeloid leukemia cells

LONP1 Targets HMGCS2 to Protect Mitochondrial Function and Attenuate Chronic Kidney Disease.

Supplementary Figure S1 from Mitochondrial Matrix Protease ClpP Agonists Inhibit Cancer Stem Cell Function in Breast Cancer Cells by Disrupting Mitochondrial Homeostasis

HSP60-regulated Mitochondrial Proteostasis and Protein Translation Promote Tumor Growth of Ovarian Cancer

Multi-omics analyses reveal ClpP activators disrupt essential mitochondrial pathways in triple-negative breast cancer

Supplementary Figure S11 from Mitochondrial Matrix Protease ClpP Agonists Inhibit Cancer Stem Cell Function in Breast Cancer Cells by Disrupting Mitochondrial Homeostasis

Small Molecule ClpP-Agonists Block Mitochondrial GRSF1 Entry by Degrading Import Machinery

Inhibition of Lonp1 induces mitochondrial remodeling and autophagy suppression in cervical cancer cells

LONP1 regulation of mitochondrial protein folding provides insight into beta cell failure in type 2 diabetes

Disuse-associated loss of the protease LONP1 in muscle impairs mitochondrial function and causes reduced skeletal muscle mass and strength

Supplementary Figure S6 from Mitochondrial Matrix Protease ClpP Agonists Inhibit Cancer Stem Cell Function in Breast Cancer Cells by Disrupting Mitochondrial Homeostasis

The Role of Lonp1 on Mitochondrial Functions during Cardiovascular and Muscular Diseases

CLU (clusterin) and PPARGC1A/PGC1α coordinately control mitophagy and mitochondrial biogenesis for oral cancer cell survival

LONP1 and mtHSP70 cooperate to promote mitochondrial protein folding

Supplementary Figure S7 from Mitochondrial Matrix Protease ClpP Agonists Inhibit Cancer Stem Cell Function in Breast Cancer Cells by Disrupting Mitochondrial Homeostasis

Mitochondrial proteostasis stress in muscle drives a long-range protective response to alleviate dietary obesity independently of ATF4